Bajaj Healthcare share price, P/E, ROE & financials

Bajaj Healthcare (BAJAJHCARE) had a P/E of 42.5× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 32% below their 52-week high. Sales and net profit fell 1.8% and 28% a year over 3 years; its ROCE of 8.4% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.51× equity, and its dividend yield is 0.5%. It is a small-cap company with a market cap of ₹1,046 Cr, ranked 70th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 31% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹320.05
Day high: ₹320.15
Day low: ₹308.85
Prev. close: ₹320.05
Volume: 1.2 L

Health check

1 fair · 5 to check

ReturnsBehind
−31.2% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 42.5 vs industry 28.7.
GrowthShrinking
Sales −1.8%, profit −28.4% a year over 3 years.
ProfitabilityWeak
ROCE 8.4% vs peer median 17.9%.
Balance sheetFair
Debt 0.51× equity, interest covered 2.4×, Piotroski 7 of 9.
Red flags2 to check
Return on equity is low at 4.8%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,046 Cr, #70 of 154 in its industry by size.

Defensive

Beta 0.28 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹656 Cr · profit ₹25 Cr

Market cap: ₹1,046 Cr; Small cap
P/E: 42.5; Industry 28.7
Price to book: 1.88; Peers 4.99
Dividend yield: 0.48%
ROE: 4.8%; Peers 14.7%
ROCE: 8.4%; Peers 17.9%
Debt to equity: 0.51; Debt ₹282 Cr
EPS (TTM): ₹7.31; Face value ₹5
OPM (TTM): 17.3%; Net margin 3.1%
Sales growth: +18.9%; Latest quarter vs a year ago
Profit growth: +20.5%; Latest quarter vs a year ago
Price to sales: 1.59; EV/EBITDA 11.9

Strengths

Quarterly profit up 20.5% on a year ago.
Quarterly sales up 18.9% on a year ago.

Risks to check

Return on equity is low at 4.8%.
32% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Bajaj Healthcare

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anthelmintic, anti viral, anti coagulant, vitamin c, anti arthritis, atypical…

Headquarters: Thane
Employees: 949
Sector: Healthcare
ISIN: INE411U01027
Website: bajajhealth.com

Price range

52 weeks

₹272.35₹458.00

Today

₹308.85₹320.15

Avg volume (3M): 1.3 L
1-year return: minus 31.2%
From 52-week high: minus 32.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
BAJAJHCAREBajaj Healthcare	310.70	minus 2.92%	1,046	42.5	1.88	8.4%	4.8%	17.3%	−1.8%	−28.4%	0.48%	minus 31.2%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Dec 25	Mar 26	Jun 26	Sep 26
149	161	153	166	176
124	131	130	137	145
24.5	30.7	22.7	28.8	31.2
16.5%	19.0%	14.8%	17.4%	17.7%
0.9	1.6	3	0.8	0.9
5.2	5.9	5.6	6.1	6
5.6	7.2	7.6	7	7.6
–	–	−33.2	–	–
14.5	19.2	−20.8	16.5	18.5
16.2%	16.3%	6.7%	15.6%	22.2%
11.8	15.7	−22.9	13.7	14.1
3.64	4.87	-7.16	4.06	4.18

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −1.8%
Profit CAGR 3Y: −28.4%
EPS CAGR 3Y: −31.7%
ROE: 4.8%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
646	473	543	611
–	minus 26.8%	+14.7%	+12.6%
524	429	460	533
122	43.8	82.9	77.8
18.8%	9.3%	15.3%	12.7%
−0.5	45	13.8	33.1
16.4	29.7	25.1	21.4
27.4	31.4	27.9	27.5
0.8	−44.3	2.3	−33.1
78.2	−16.7	46	28.9
18.7%	14.1%	6.7%	26.3%
43	−83.8	39.5	15.8
–	minus 294.8%	–	minus 60.1%
15.59	-30.36	13.12	4.97

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.8	13.8	15.8	16.8
354	265	450	516
415	333	223	249
115	154	144	141
898	765	833	923
386	258	240	255
20.3	4.8	3.4	7.9
0	0	0	0
19.2	2.9	6.7	39.1
472	500	582	621
898	765	833	923

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−22.2	92.3	21.6	58.1
−93.4	−11.2	−14.8	−47.8
131	−96.6	−6.4	24.3
15.7	−15.5	0.4	34.6
−93.6	−30.3	−11.5	−43.3
−116	62	10.1	14.7
−4.1	−2.8	−2.8	−3.2

Shareholding pattern

Source: NSE filings

58.6%

promoters

Promoters58.59%
Public41.41%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	58.59%	41.41%	0.00
30 Jun 2026	58.59%	41.41%	plus 0.30
31 Mar 2026	58.29%	41.71%	0.00
18 Mar 2026	58.29%	41.71%	minus 0.90
31 Dec 2025	59.19%	40.81%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you